Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy

@inproceedings{Flingai2015ProtectionAD,
  title={Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy},
  author={Seleeke Flingai and Emily M. Plummer and Ami S. Patel and Sujan Shresta and Janess M. Mendoza and Kate E Broderick and Niranjan Y Sardesai and Kar Muthumani and David B. Weiner},
  booktitle={Scientific reports},
  year={2015}
}
Dengue virus (DENV) is the most important mosquito-borne viral infection in humans. In recent years, the number of cases and outbreaks has dramatically increased worldwide. While vaccines are being developed, none are currently available that provide balanced protection against all DENV serotypes. Advances in human antibody isolation have uncovered DENV neutralizing antibodies (nAbs) that are capable of preventing infection from multiple serotypes. Yet delivering monoclonal antibodies using… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 26 times over the past 90 days. VIEW TWEETS
20 Citations
41 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

  • L Villar
  • N. Engl. J. Med
  • 2014

a phase 3, randomised, observer-masked, placebo-controlled trial

  • Capeding, M. R. et al. Clinical efficacy, safety of a novel tetravalent dengue vaccine in healthy c Asia
  • Lancet 384, 1358–1365
  • 2014

Similar Papers

Loading similar papers…